{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T12:02:58Z","timestamp":1784721778090,"version":"3.55.0"},"reference-count":137,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.revmed.2026.05.006","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T11:24:09Z","timestamp":1784719449000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Uv\u00e9ites sarco\u00efdosiques\u00a0: pr\u00e9sent et futur"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3070-3842","authenticated-orcid":false,"given":"Pascal","family":"S\u00e8ve","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"El Jammal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmine","family":"Serrar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvan","family":"Jamilloux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Kodjikian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6084-995X","authenticated-orcid":false,"given":"Robin","family":"Jacquot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2026.05.006_bib0690","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(13)60680-7","article-title":"Sarcoidosis","volume":"383","author":"Valeyre","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2026.05.006_bib0695","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMra2101555","article-title":"Challenges of sarcoidosis and its management","volume":"385","author":"Drent","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2026.05.006_bib0700","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1136\/thx.2007.094060","article-title":"Heredity in sarcoidosis: a registry-based twin study","volume":"63","author":"Sverrild","year":"2008","journal-title":"Thorax"},{"key":"10.1016\/j.revmed.2026.05.006_bib0705","doi-asserted-by":"crossref","first-page":"1800385","DOI":"10.1183\/13993003.00385-2018","article-title":"Familial aggregation and heritability of sarcoidosis: a Swedish nested case-control study","volume":"52","author":"Rossides","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.revmed.2026.05.006_bib0710","article-title":"Familial aggregation of sarcoidosis. A case-control etiologic study of sarcoidosis (ACCESS)","volume":"164","author":"Rybicki","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.revmed.2026.05.006_bib0715","doi-asserted-by":"crossref","first-page":"103323","DOI":"10.1016\/j.jaut.2024.103323","article-title":"Extrapulmonary sarcoidosis","volume":"149","author":"Spagnolo","year":"2024","journal-title":"J Autoimmun"},{"key":"10.1016\/j.revmed.2026.05.006_bib0720","doi-asserted-by":"crossref","first-page":"1700991","DOI":"10.1183\/13993003.00991-2017","article-title":"Phenotypes of organ involvement in sarcoidosis","volume":"51","author":"Schupp","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.revmed.2026.05.006_bib0725","doi-asserted-by":"crossref","first-page":"2001160","DOI":"10.1183\/13993003.01160-2020","article-title":"Clinical phenotypes of extrapulmonary sarcoidosis: an analysis of a French, multi-ethnic, multicentre cohort","volume":"57","author":"Lhote","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.revmed.2026.05.006_bib0730","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1600-0420.2006.00791.x","article-title":"Pattern of ocular manifestations in patients with sarcoidosis in developing countries","volume":"85","author":"Khanna","year":"2007","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1016\/j.revmed.2026.05.006_bib0735","doi-asserted-by":"crossref","first-page":"9440","DOI":"10.1038\/s41598-018-27554-3","article-title":"Nationwide survey on the organ-specific prevalence and its interaction with sarcoidosis in Japan","volume":"8","author":"Hattori","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.revmed.2026.05.006_bib0740","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/09273948.2025.2563707","article-title":"Sarcoid uveitis epidemiology, systemic treatment, and complications: a large United States National Database Study","volume":"34","author":"Shakarchi","year":"2026","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.revmed.2026.05.006_bib0745","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/09273948.2024.2369931","article-title":"Clinical patterns of sarcoidosis patients with and without uveitis: insights from a Dutch Sarcoidosis Centre","volume":"33","author":"Ku\u010d","year":"2025","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.revmed.2026.05.006_bib0750","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/aos.16738","article-title":"Risk factors for uveitis in a Finnish sarcoid population","volume":"103","author":"Joukainen","year":"2025","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.revmed.2026.05.006_bib0755","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.revmed.2022.10.001","article-title":"[Sarcoid uveitis: ophthalmologist's and internist's viewpoints]","volume":"44","author":"S\u00e8ve","year":"2023","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2026.05.006_bib0760","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1007\/s00417-019-04411-1","article-title":"Clinical and etiologic characteristics of de novo uveitis in patients aged 60\u00a0years and above: experience of a French tertiary center","volume":"257","author":"Grumet","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.revmed.2026.05.006_bib0765","first-page":"133","article-title":"Changes in patterns of uveitis at a tertiary referral center in Northern Italy: analysis of 990 consecutive cases","volume":"38","author":"Luca","year":"2018","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.revmed.2026.05.006_bib0770","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/08820538.2021.1885721","article-title":"Epidemiology of uveitis in a tertiary care centre in Portugal","volume":"36","author":"Hermann","year":"2021","journal-title":"Semin Ophthalmol"},{"key":"10.1016\/j.revmed.2026.05.006_bib0775","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2147\/OPTH.S80972","article-title":"Epidemiology of uveitis in the mid-Atlantic United States","volume":"9","author":"Bajwa","year":"2015","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.revmed.2026.05.006_bib0780","doi-asserted-by":"crossref","first-page":"102351","DOI":"10.1016\/j.autrev.2019.102351","article-title":"Uveitis: autoimmunity\u2026 and beyond","volume":"18","author":"Bertrand","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.revmed.2026.05.006_bib0785","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2174\/157340561501181207091552","article-title":"FDG-PET imaging in sarcoidosis","volume":"15","author":"Tana","year":"2019","journal-title":"Curr Med Imaging Rev"},{"key":"10.1016\/j.revmed.2026.05.006_bib0790","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ajo.2021.03.003","article-title":"Systemic associations of sarcoid uveitis: correlation with uveitis phenotype and ethnicity","volume":"229","author":"Niederer","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.revmed.2026.05.006_bib0795","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1136\/bjophthalmol-2016-309767","article-title":"Long-term visual and systemic prognoses of 83 cases of biopsy-proven sarcoid uveitis","volume":"101","author":"Rochepeau","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.revmed.2026.05.006_bib0800","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ajo.2018.09.013","article-title":"Sarcoidosis-related uveitis: clinical presentation, disease course, and rates of systemic disease progression after uveitis diagnosis","volume":"198","author":"Ma","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.revmed.2026.05.006_bib0805","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/BF00153496","article-title":"Risk factors for ocular sarcoidosis","volume":"72","author":"Rothova","year":"1989","journal-title":"Doc Ophthalmol"},{"key":"10.1016\/j.revmed.2026.05.006_bib0810","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1136\/bjophthalmol-2014-306353","article-title":"Clinical features and diagnostic evaluation of 83 biopsy-proven sarcoid uveitis cases","volume":"99","author":"Febvay","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.revmed.2026.05.006_bib0815","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ajo.2022.06.001","article-title":"Identification of multidimensional phenotypes using cluster analysis in sarcoid uveitis patients","volume":"242","author":"Fermon","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.revmed.2026.05.006_bib0820","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1055\/s-0040-1710536","article-title":"Ocular sarcoidosis","volume":"41","author":"S\u00e8ve","year":"2020","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.revmed.2026.05.006_bib0825","doi-asserted-by":"crossref","first-page":"E3894","DOI":"10.3390\/jcm9123894","article-title":"Factors associated with ocular and extraocular recovery in 143 patients with sarcoid uveitis","volume":"9","author":"Bienvenu","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.revmed.2026.05.006_bib0830","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.2147\/OPTH.S278373","article-title":"Ocular manifestations of sarcoidosis in a South Florida population","volume":"14","author":"Laura","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.revmed.2026.05.006_bib0835","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.autrev.2014.04.001","article-title":"Sarcoidosis and uveitis","volume":"13","author":"Jamilloux","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.revmed.2026.05.006_bib0840","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1007\/s00417-019-04415-x","article-title":"Ethnicity and association with ocular, systemic manifestations and prognosis in 194 patients with sarcoid uveitis","volume":"257","author":"Coulon","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.revmed.2026.05.006_bib0845","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1136\/bjophthalmol-2018-313356","article-title":"Revised criteria of International Workshop on Ocular Sarcoidosis (IWOS) for the diagnosis of ocular sarcoidosis","volume":"103","author":"Mochizuki","year":"2019","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.revmed.2026.05.006_bib0850","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ajo.2021.03.047","article-title":"classification criteria for sarcoidosis-associated uveitis","volume":"228","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.revmed.2026.05.006_bib0855","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.3390\/jcm12093194","article-title":"Sarcoidosis-related uveitis: a review","volume":"12","author":"Giorgiutti","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.revmed.2026.05.006_bib0860","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1164\/rccm.202002-0251ST","article-title":"Diagnosis and detection of sarcoidosis. An official American Thoracic Society Clinical Practice Guideline","volume":"201","author":"Crouser","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.revmed.2026.05.006_bib0865","doi-asserted-by":"crossref","first-page":"2004079","DOI":"10.1183\/13993003.04079-2020","article-title":"ERS clinical practice guidelines on treatment of sarcoidosis","volume":"58","author":"Baughman","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.revmed.2026.05.006_bib0870","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/thoraxjnl-2019-214348","article-title":"BTS Clinical Statement on pulmonary sarcoidosis","volume":"76","author":"Thillai","year":"2021","journal-title":"Thorax"},{"key":"10.1016\/j.revmed.2026.05.006_bib0875","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s12348-011-0029-7","article-title":"Ocular disease awareness and pattern of ocular manifestation in patients with biopsy-proven lung sarcoidosis","volume":"1","author":"Pefkianaki","year":"2011","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"10.1016\/j.revmed.2026.05.006_bib0880","doi-asserted-by":"crossref","first-page":"107562","DOI":"10.1016\/j.rmed.2024.107562","article-title":"Role of screening for uveitis in subjects with sarcoidosis","volume":"224","author":"Koh","year":"2024","journal-title":"Respir Med"},{"key":"10.1016\/j.revmed.2026.05.006_bib0885","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1080\/09273948.2021.1976216","article-title":"The role of screening for asymptomatic ocular inflammation in sarcoidosis","volume":"30","author":"Lee","year":"2022","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.revmed.2026.05.006_bib0890","first-page":"2172","article-title":"Should patients with sarcoidosis be screened for asymptomatic ocular inflammation?","volume":"58","author":"Sunshine","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.revmed.2026.05.006_bib0895","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/aos.15749","article-title":"Low utility of ocular screening in sarcoidosis in Finland","volume":"102","author":"Joukainen","year":"2024","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.revmed.2026.05.006_bib0900","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1080\/09273948.2022.2073238","article-title":"Prevalence of positive QuantiFERON-TB Test among sarcoid uveitis patients and its clinical implications in a country non-endemic for tuberculosis","volume":"31","author":"Garneret","year":"2023","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.revmed.2026.05.006_bib0905","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3109\/09273948.2015.1115082","article-title":"High resolution chest computerized tomography in the diagnosis of ocular sarcoidosis in a high TB endemic population","volume":"25","author":"Babu","year":"2017","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.revmed.2026.05.006_bib0910","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12886-016-0194-4","article-title":"The serum angiotensin converting enzyme and lysozyme levels in patients with ocular involvement of autoimmune and infectious diseases","volume":"16","author":"Sahin","year":"2016","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.revmed.2026.05.006_bib0915","first-page":"1571","article-title":"Comparative evaluation of 18F-FDG PET and 67Ga scintigraphy in patients with sarcoidosis","volume":"47","author":"Nishiyama","year":"2006","journal-title":"J Nucl Med"},{"key":"10.1016\/j.revmed.2026.05.006_bib0920","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/09273948.2023.2226203","article-title":"Value of chest X-ray and chest computed tomography for systemic sarcoidosis diagnosis in undifferentiated uveitis","volume":"32","author":"Borciuch","year":"2024","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.revmed.2026.05.006_bib0925","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1136\/bjophthalmol-2020-316563","article-title":"Diagnostic value of lymphopaenia and elevated serum ACE in patients with uveitis","volume":"105","author":"Cotte","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.revmed.2026.05.006_bib0930","first-page":"149","article-title":"ATS\/ERS\/WASOG statement on sarcoidosis. American Thoracic Society\/European Respiratory Society\/World Association of Sarcoidosis and other Granulomatous Disorders","volume":"16","author":"Hunninghake","year":"1999","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.revmed.2026.05.006_bib0935","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/art.20839","article-title":"Association of peripheral multifocal choroiditis with sarcoidosis: a study of thirty-seven patients","volume":"51","author":"Abad","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2026.05.006_bib0940","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1055\/s-0037-1602382","article-title":"Ocular involvement in sarcoidosis","volume":"38","author":"Groen","year":"2017","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.revmed.2026.05.006_bib0945","article-title":"Clinical manifestations, complications and treatment of ocular sarcoidosis: correlation between visual efficiency and macular edema as seen on optical coherence tomography","volume":"1\u20138","author":"Paovic","year":"2016","journal-title":"Semin Ophthalmol"},{"key":"10.1016\/j.revmed.2026.05.006_bib0950","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ophtha.2025.10.020","article-title":"Factors associated with ocular relapse and visual prognosis in sarcoid uveitis","volume":"133","author":"Abramowicz","year":"2026","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2026.05.006_bib0955","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1136\/bjo.84.1.110","article-title":"Ocular involvement in sarcoidosis","volume":"84","author":"Rothova","year":"2000","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.revmed.2026.05.006_bib0960","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ophtha.2006.05.074","article-title":"Differences in clinical findings between Caucasians and African Americans with biopsy-proven sarcoidosis","volume":"114","author":"Evans","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2026.05.006_bib0965","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/eye.1997.77","article-title":"Clinical diagnosis of ocular sarcoidosis","volume":"11","author":"Stavrou","year":"1997","journal-title":"Eye"},{"key":"10.1016\/j.revmed.2026.05.006_bib0970","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10384-022-00927-y","article-title":"Clinical features of ocular sarcoidosis: severe, refractory, and prolonged inflammation","volume":"66","author":"Suzuki","year":"2022","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.revmed.2026.05.006_bib0975","doi-asserted-by":"crossref","first-page":"106340","DOI":"10.1016\/j.ejim.2025.05.005","article-title":"Diagnostic contribution of minor salivary glands biopsy in clinical practice","volume":"140","author":"Mauclin","year":"2025","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.revmed.2026.05.006_bib0980","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/0002-9394(84)90374-X","article-title":"Diagnosing sarcoidosis by transconjunctival biopsy of the lacrimal gland","volume":"97","author":"Weinreb","year":"1984","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.revmed.2026.05.006_bib0985","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1136\/bjophthalmol-2011-300129","article-title":"Minor salivary gland biopsy in diagnosing ocular sarcoidosis","volume":"95","author":"Blaise","year":"2011","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.revmed.2026.05.006_bib0990","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00417-012-2178-2","article-title":"Ocular sarcoidosis: when should labial salivary gland biopsy be performed?","volume":"251","author":"Bernard","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.revmed.2026.05.006_bib0995","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/0002-9343(59)90242-6","article-title":"Ocular sarcoidosis","volume":"26","author":"James","year":"1959","journal-title":"Am J Med"},{"key":"10.1016\/j.revmed.2026.05.006_bib1000","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S1726-4901(09)70311-9","article-title":"Conjunctival biopsy in sarcoidosis","volume":"69","author":"Chung","year":"2006","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.revmed.2026.05.006_bib1005","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/bjo.74.8.469","article-title":"Conjunctival biopsy in the diagnosis of sarcoidosis","volume":"74","author":"Spaide","year":"1990","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.revmed.2026.05.006_bib1010","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1136\/bmj.2.4949.1180","article-title":"Conjunctival biopsy in sarcoidosis","volume":"2","author":"Crick","year":"1955","journal-title":"Br Med J"},{"key":"10.1016\/j.revmed.2026.05.006_bib1015","doi-asserted-by":"crossref","first-page":"2411806","DOI":"10.1080\/25310429.2024.2411806","article-title":"Ultrathin bronchoscopy-guided small airway biopsy for diagnosing sarcoidosis: a prospective study","volume":"31","author":"Trisolini","year":"2025","journal-title":"Pulmonology"},{"key":"10.1016\/j.revmed.2026.05.006_bib1020","doi-asserted-by":"crossref","first-page":"00203","DOI":"10.1183\/23120541.00203-2019","article-title":"Diagnostic yield and safety of transbronchial cryobiopsy in sarcoidosis","volume":"5","author":"Jacob","year":"2019","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.revmed.2026.05.006_bib1025","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1055\/s-0040-1710536","article-title":"Ocular sarcoidosis","volume":"41","author":"S\u00e8ve","year":"2020","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.revmed.2026.05.006_bib1030","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1136\/bjophthalmol-2020-317354","article-title":"Recommendations for the management of ocular sarcoidosis from the International Workshop on Ocular Sarcoidosis","volume":"105","author":"Takase","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.revmed.2026.05.006_bib1035","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.revmed.2023.04.002","article-title":"French recommendations for the management of non-infectious chronic uveitis","volume":"44","author":"Quartier","year":"2023","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2026.05.006_bib1040","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.ophtha.2009.04.020","article-title":"Methotrexate for ocular inflammatory diseases","volume":"116","author":"Gangaputra","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2026.05.006_bib1045","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1080\/09273948.2023.2165952","article-title":"Hydroxychloroquine therapy in sarcoidosis-associated uveitis","volume":"32","author":"Bert","year":"2024","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.revmed.2026.05.006_bib1050","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jfo.2014.04.010","article-title":"[Safety and efficacy of subconjunctival triamcinolone injections in the management of uveitic macular edema: retrospective study of thirty-one cases]","volume":"37","author":"Bleriot","year":"2014","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.revmed.2026.05.006_bib1055","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jfo.2016.11.013","article-title":"[Treatment of macular edema: comparison of efficacy and tolerability of subconjunctival triamcinolone injections, sub-tenon's triamcinolone injections and intravitreal dexamethasone implant]","volume":"40","author":"Carbonni\u00e8re","year":"2017","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.revmed.2026.05.006_bib1060","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1001\/archophthalmol.2010.339","article-title":"Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis","volume":"129","author":"Lowder","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.revmed.2026.05.006_bib1065","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ajo.2015.10.009","article-title":"Evaluation of objective vitritis grading method using optical coherence tomography: influence of phakic status and previous vitrectomy","volume":"161","author":"Zarranz-Ventura","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.revmed.2026.05.006_bib1070","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/j.ophtha.2014.02.003","article-title":"Treatment with repeat dexamethasone implants results in long-term disease control in eyes with noninfectious uveitis","volume":"121","author":"Tomkins-Netzer","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2026.05.006_bib1075","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1159\/000362178","article-title":"Long-term outcome of an intravitreal dexamethasone implant for the treatment of noninfectious uveitic macular edema","volume":"232","author":"Habot-Wilner","year":"2014","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.revmed.2026.05.006_bib1080","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1007\/s12325-019-00989-4","article-title":"Intravitreal dexamethasone implant for treatment of sarcoidosis-related uveitis","volume":"36","author":"Kim","year":"2019","journal-title":"Adv Ther"},{"key":"10.1016\/j.revmed.2026.05.006_bib1085","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3928\/23258160-20150101-09","article-title":"Dexamethasone intravitreal implant for pseudophakic cystoid macular edema in patients with diabetes","volume":"46","author":"Khurana","year":"2015","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.revmed.2026.05.006_bib1090","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.ophtha.2024.02.019","article-title":"Treatment of noninfectious uveitic macular edema with periocular and intraocular corticosteroid therapies: a report by the American Academy of Ophthalmology","volume":"131","author":"Smith","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2026.05.006_bib1095","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ophtha.2018.08.021","article-title":"Periocular triamcinolone vs. intravitreal triamcinolone vs. intravitreal dexamethasone implant for the treatment of uveitic macular edema: the PeriOcular vs. INTravitreal corticosteroids for uveitic macular edema (POINT) Trial","volume":"126","author":"Thorne","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2026.05.006_bib1100","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.ophtha.2018.10.033","article-title":"Effect of an injectable fluocinolone acetonide insert on recurrence rates in chronic noninfectious uveitis affecting the posterior segment: twelve-month results","volume":"126","author":"Jaffe","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2026.05.006_bib1105","doi-asserted-by":"crossref","first-page":"100403","DOI":"10.1016\/j.xops.2023.100403","article-title":"The 0.2-\u03bcg\/day fluocinolone acetonide intravitreal implant in chronic noninfectious posterior uveitis: a 3-year randomized trial in India","volume":"4","author":"Biswas","year":"2024","journal-title":"Ophthalmol Sci"},{"key":"10.1016\/j.revmed.2026.05.006_bib1110","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12886-026-04661-8","article-title":"Clinical effectiveness of the 0.18 mg fluocinolone acetonide intravitreal implant for non-infectious uveitis-associated macular edema: a real-world study","volume":"26","author":"Chen","year":"2026","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.revmed.2026.05.006_bib1115","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3390\/jpm14030245","article-title":"Efficacity and safety of the fluocinolone acetonide implant in uveitic macular edema: a real-life study from the French Uveitis Network","volume":"14","author":"Jabbour","year":"2024","journal-title":"J Pers Med"},{"key":"10.1016\/j.revmed.2026.05.006_bib1120","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1080\/09273948.2025.2478207","article-title":"Long-term treatment outcomes with a single 0.19\u00a0mg fluocinolone acetonide implant in non-infectious uveitis\u00a0\u2013\u00a0A real-world study","volume":"33","author":"Darwisch","year":"2025","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.revmed.2026.05.006_bib1125","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3390\/biomedicines13020248","article-title":"A meta-analysis of the efficacy and safety of the 0.19\u00a0mg fluocinolone acetonide implant in non-infectious uveitis","volume":"13","author":"Yeo","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.revmed.2026.05.006_bib1130","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S2213-2600(25)00338-8","article-title":"A paradigm shift in corticosteroid therapy for sarcoidosis: a World Association of Sarcoidosis and Other Granulomatous Disorders Position Paper, endorsed by the Americas Association of Sarcoidosis and Other Granulomatous Disorders","volume":"14","author":"Wells","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.revmed.2026.05.006_bib1135","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ophtha.2017.11.017","article-title":"Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: Fundamentals Of Care for UveitiS (FOCUS) Initiative","volume":"125","author":"Dick","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2026.05.006_bib1140","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1001\/jama.2019.12618","article-title":"Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs. methotrexate on inflammation in patients with uveitis: a randomized clinical trial","volume":"322","author":"Rathinam","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.revmed.2026.05.006_bib1145","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/bjo-2024-325163","article-title":"Methotrexate versus conventional disease-modifying antirheumatic drugs in the treatment of non-anterior sarcoidosis-associated uveitis","volume":"109","author":"Leclercq","year":"2024","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.revmed.2026.05.006_bib1150","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.ophtha.2025.05.026","article-title":"Corticosteroids with or without conventional disease-modifying antirheumatic drug as first-line therapy in nonanterior sarcoidosis uveitis","volume":"132","author":"Jacquot","year":"2025","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2026.05.006_bib1155","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1212\/WNL.0000000000003431","article-title":"Treatment of neurosarcoidosis: a comparative study of methotrexate and mycophenolate mofetil","volume":"87","author":"Bitoun","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.revmed.2026.05.006_bib1160","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1056\/NEJMoa2501443","article-title":"First-line treatment of pulmonary sarcoidosis with prednisone or methotrexate","volume":"393","author":"Kahlmann","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2026.05.006_bib1165","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial","volume":"388","author":"Nguyen","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2026.05.006_bib1170","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in patients with active noninfectious uveitis","volume":"375","author":"Jaffe","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2026.05.006_bib1175","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","article-title":"2018 update of the EULAR recommendations for the management of Beh\u00e7et's syndrome","volume":"77","author":"Hatemi","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2026.05.006_bib1180","first-page":"310","article-title":"Adalimumab versus Conventional Immunosuppression for Uveitis (ADVISE) Trial","volume":"133","author":"Adalimumab versus Conventional Immunosuppression for Uveitis Trial Research Group","year":"2025","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2026.05.006_bib1185","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ophtha.2024.10.010","article-title":"Efficacy of subcutaneous and intravenous tocilizumab in noninfectious uveitis","volume":"132","author":"Kherani","year":"2025","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2026.05.006_bib1190","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1136\/annrheumdis-2017-212089","article-title":"ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis","volume":"77","author":"Quartier","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2026.05.006_bib1195","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ophtha.2018.09.044","article-title":"Efficacy and safety of sarilumab for the treatment of posterior segment noninfectious uveitis (SARIL-NIU): the phase 2 SATURN Study","volume":"126","author":"Heissigerov\u00e1","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2026.05.006_bib1200","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ophtha.2021.11.013","article-title":"Anti-tumor necrosis factor \u03b1 versus tocilizumab in the treatment of refractory uveitic macular edema: a multicenter study from the French Uveitis Network","volume":"129","author":"Leclercq","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2026.05.006_bib1205","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ajo.2026.01.037","article-title":"Adalimumab, anakinra and tocilizumab in patients with non-infectious uveitis: a multicenter randomized controlled trial","volume":"285","author":"Saadoun","year":"2026","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.revmed.2026.05.006_bib1210","first-page":"74","article-title":"Efficacy and safety of TNF antagonists in ocular sarcoidosis: data from the French registry STAT","volume":"34","author":"Marquet","year":"2017","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.revmed.2026.05.006_bib1215","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00417-011-1844-0","article-title":"Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis","volume":"250","author":"Erckens","year":"2012","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.revmed.2026.05.006_bib1220","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/thorax-2025-223014","article-title":"Systematic review and meta-analysis of the efficacy of biologic and targeted synthetic therapies in sarcoidosis","volume":"80","author":"Bechman","year":"2025","journal-title":"Thorax"},{"key":"10.1016\/j.revmed.2026.05.006_bib1225","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1136\/bjophthalmol-2021-319072","article-title":"Therapeutic drug monitoring guides the management of patients with chronic non-infectious uveitis treated with adalimumab: a retrospective study","volume":"106","author":"Sejournet","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.revmed.2026.05.006_bib1230","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ajo.2022.03.017","article-title":"Long-term follow-up of patients with uveitis treated with adalimumab: response rates and reasons for discontinuation of therapy","volume":"240","author":"Eurelings","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.revmed.2026.05.006_bib1235","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1080\/09273948.2025.2486371","article-title":"Influence of immunogenicity of adalimumab on prognosis of patients with non-infectious-uveitis: a systematic review","volume":"33","author":"Fern\u00e1ndez-Nogueras","year":"2025","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.revmed.2026.05.006_bib1240","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1080\/09273948.2025.2479802","article-title":"Effectiveness of frequently used TNF inhibitors vs. conventional immunosuppressive therapies for noninfectious uveitis","volume":"33","author":"Gangaputra","year":"2025","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.revmed.2026.05.006_bib1245","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ophtha.2025.09.019","article-title":"Evaluating the effectiveness of escalating to weekly adalimumab dosing for the treatment of noninfectious uveitis: a multicenter study","volume":"133","author":"Pillar","year":"2026","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2026.05.006_bib1250","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3109\/09273948.2014.967779","article-title":"Certolizumab pegol, a new anti-TNF-\u03b1 in the armamentarium against ocular inflammation","volume":"24","author":"Lloren\u00e7","year":"2016","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.revmed.2026.05.006_bib1255","first-page":"680","article-title":"Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitis","volume":"37","author":"Tosi","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.revmed.2026.05.006_bib1260","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.ophtha.2025.05.014","article-title":"Comparative effectiveness of intravenous versus subcutaneous tocilizumab for refractory uveitis: a retrospective analysis","volume":"132","author":"Leclercq","year":"2025","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2026.05.006_bib1265","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1167\/iovs.66.11.67","article-title":"Machine learning for predicting recurrent course in uveitis using baseline clinical characteristics","volume":"66","author":"Rojas-Carabali","year":"2025","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.revmed.2026.05.006_bib1270","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.3390\/jcm11133606","article-title":"Comprehensive proteomic profiling of vitreous humor in ocular sarcoidosis compared with other vitreoretinal diseases","volume":"11","author":"Komatsu","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.revmed.2026.05.006_bib1275","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/aos.14993","article-title":"Vitreous proteomics, a gateway to improved understanding and stratification of diverse uveitis aetiologies","volume":"100","author":"Schrijver","year":"2022","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.revmed.2026.05.006_bib1280","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1167\/iovs.16-20324","article-title":"Association of high-mobility group box-1 with Th cell-related cytokines in the vitreous of ocular sarcoidosis patients","volume":"58","author":"Takeuchi","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.revmed.2026.05.006_bib1285","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1167\/iovs.11-9244","article-title":"Simultaneous analysis of multiple cytokines in the vitreous of patients with sarcoid uveitis","volume":"53","author":"Nagata","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.revmed.2026.05.006_bib1290","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s00011-022-01601-2","article-title":"Could different aqueous humor and plasma cytokine profiles help differentiate between ocular sarcoidosis and ocular tuberculosis?","volume":"71","author":"De Simone","year":"2022","journal-title":"Inflamm Res"},{"key":"10.1016\/j.revmed.2026.05.006_bib1295","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1016\/j.ophtha.2012.05.033","article-title":"The CD4\/CD8 ratio in vitreous fluid is of high diagnostic value in sarcoidosis","volume":"119","author":"Kojima","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2026.05.006_bib1300","doi-asserted-by":"crossref","first-page":"32737","DOI":"10.1038\/s41598-025-18121-8","article-title":"Fatty acid degradation-related gene signatures as biomarkers for ocular sarcoidosis","volume":"15","author":"Wu","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.revmed.2026.05.006_bib1305","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1001\/jamaophthalmol.2015.0726","article-title":"Parallel gene expression changes in sarcoidosis involving the lacrimal gland, orbital tissue, or blood","volume":"133","author":"Rosenbaum","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.revmed.2026.05.006_bib1310","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/MCP.0000000000000985","article-title":"Personalized medicine in sarcoidosis: unravelling biomarkers for targeted care","volume":"29","author":"Francesqui","year":"2023","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.revmed.2026.05.006_bib1315","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.it.2024.04.013","article-title":"Sarcoidosis immunopathogenesis\u00a0\u2013\u00a0a new concept of maladaptive trained immunity","volume":"45","author":"Robert","year":"2024","journal-title":"Trends Immunol"},{"key":"10.1016\/j.revmed.2026.05.006_bib1320","doi-asserted-by":"crossref","first-page":"1801482","DOI":"10.1183\/13993003.01482-2018","article-title":"Dramatic response of refractory sarcoidosis under ruxolitinib in a patient with associated JAK2-mutated polycythemia","volume":"52","author":"Rotenberg","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.revmed.2026.05.006_bib1325","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1136\/annrheumdis-2019-215387","article-title":"Refractory sarcoidosis-like systemic granulomatosis responding to ruxolitinib","volume":"78","author":"Levraut","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2026.05.006_bib1330","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1056\/NEJMoa1805958","article-title":"Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis","volume":"379","author":"Damsky","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2026.05.006_bib1335","first-page":"17246","article-title":"Janus kinase inhibitors in pulmonary and extra-pulmonary sarcoidosis: a case series and a systematic review of the literature","volume":"42","author":"Quaggetto","year":"2025","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.revmed.2026.05.006_bib1340","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1038\/s41467-022-30615-x","article-title":"Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis","volume":"13","author":"Damsky","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.revmed.2026.05.006_bib1345","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/jamaophthalmol.2024.2439","article-title":"Filgotinib in active noninfectious uveitis: the HUMBOLDT Randomized Clinical Trial","volume":"142","author":"Srivastava","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.revmed.2026.05.006_bib1350","doi-asserted-by":"crossref","first-page":"1439338","DOI":"10.3389\/fmed.2024.1439338","article-title":"Efficacy and safety of Janus kinase inhibitors in non-infectious inflammatory ocular diseases: a prospective cohort study from the international AIDA network registries","volume":"11","author":"Vitale","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.revmed.2026.05.006_bib1355","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12969-021-00634-x","article-title":"Tofacitinib effectiveness in Blau syndrome: a case series of Chinese paediatric patients","volume":"19","author":"Zhang","year":"2021","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.revmed.2026.05.006_bib1360","doi-asserted-by":"crossref","first-page":"225","DOI":"10.55563\/clinexprheumatol\/3gymd4","article-title":"Resolution of ocular and mediastinal sarcoidosis after Janus kinase inhibitor therapy for concomitant rheumatoid arthritis","volume":"39","author":"Sejournet","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.revmed.2026.05.006_bib1365","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1016\/j.ophtha.2016.07.029","article-title":"Intravitreal sirolimus for noninfectious uveitis: a phase III Sirolimus Study Assessing Double-masKed Uveitis TReAtment (SAKURA)","volume":"123","author":"Nguyen","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.revmed.2026.05.006_bib0685","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1016\/S2665-9913(23)00302-8","article-title":"Efficacy and safety of mTOR inhibition in cutaneous sarcoidosis: a single-centre trial","volume":"6","author":"Redl","year":"2024","journal-title":"Lancet Rheumatol"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866326005734?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866326005734?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T11:24:30Z","timestamp":1784719470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866326005734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":137,"alternative-id":["S0248866326005734"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2026.05.006","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Uv\u00e9ites sarco\u00efdosiques\u00a0: pr\u00e9sent et futur","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2026.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}